A role of budesonide/formoterol fixed combination in the treatment of stable chronic obstructive pulmonary disease. A conclusion of the Expert Council of the Volga Federal district of Russia

Овчаренко, С. И.; Визель, А. А.; Gamova, I.; Добротина, И. С.; Загидуллин, Ш. З.; Купаев, В. И.; Недашковская, Н. Г.; Postnikova, Larisa; Уханова, О П; Фассахов, Р. С.; Хамитов, Р. Ф.

doi:10.18093/0869-0189-2017-27-1-114-121

Cited by 3 publications

(1 citation statement)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Об этом свидетельствуют многочисленные исследования [17,24]. Предпочтение отдается фиксированным комбинациям бронходилататоров (будесонид/формотерол, ипратропия бромид/фенотерол, сальметерол/флутиказон) [2,23,40]. Ингаляционные глюкокортикостероиды (ИГКС) при плановом лечении ХОБЛ улучшают симптоматику, функциональные показатели, качество жизни, уменьшают частоту обострений у больных при ОФВ 1 <60% от должного.…”

unclassified

Outpatient pulmonology in contemporary national recommendations and research

Kruglyakova

Bugaeva

2019

Bûlletenʹ fiziologii i patologii dyhaniâ

View full text Add to dashboard Cite

Обзоры Reviews Контактная информация Людмила Ивановна Бугаева, канд. мед. наук, ассистент кафедры факультетской и поликлинической терапии Федерального государственного бюджетного образовательного учреждения высшего образования «Амурская государственная медицинская академия» Министерства здравоохранения Российской Федерации, 675000, г. Благовещенск, ул. Горького, 95.

show abstract

unclassified

Outpatient pulmonology in contemporary national recommendations and research

Kruglyakova

Bugaeva

2019

Bûlletenʹ fiziologii i patologii dyhaniâ

View full text Add to dashboard Cite

show abstract

Peripheral blood eosinophil count in COPD: literature data and new findings

Визель

Салахова

Визель

et al. 2022

Pulʹmonologiâ (Mosk.)

View full text Add to dashboard Cite

Eosinophils play a protective role and are involved in the pathogenesis of exacerbations in chronic obstructive pulmonary disease (COPD). The study of the role of eosinophils in pathogenesis of COPD, especially during exacerbations, is relevant to selecting the optimal therapy. The aim was to analyze literature data and compare them with the results of our study in real clinical practice. Methods. We analyzed the publications on eosinophil count in COPD in electronic libraries eLIBRARY and National Library of Medicine. In our study, we examined 330 patients, collected their history, and conducted physical examination, spirometry, and laboratory tests. Statistical analysis was carried out using SPSS-18 software.Results. Analysis of publications showed that percent of patients with COPD with a stable eosinophil count of more than 300 cells/μL varies from 12.3% to 17%. This percentage is variable and can reach 37.5% in patients with exacerbations. As many studies show, eosinophilia is one of the indications for inhaled corticosteroids (ICS) and is associated with better outcomes than eosinopenia. In our study, 18.58% of patients were eligible for ICSs because of their eosinophil count, 53.3% because of > 2 exacerbations, 82.1% because of exacerbations or hospitalizations, and 62.1% because their FEV1 was < 50% of the reference value. Among patients with FEV1 < 50%, 61% had > 2 exacerbations, 87.8% had hospitalizations, and 12.7% had eosinophilia. Only 7.57% of patients with COPD met all three criteria for prescribing ICS. 16.2% of patients had eosinophilia and 2 and more exacerbations within a year. 10.3% of patients had eosinophilia combined with FEV1 less than 50%. 6.7% of patients had eosinophilia, 2 or more exacerbations within a year, and FEV1 < 50%. Conclusion. Analysis of literature data and our findings have shown that the eosinophil blood count is one of the important prognostic indicators in COPD. It facilitates selection of the optimal therapy, including triple inhalation therapy.

show abstract

Clinical experience of using formoterol/budesonide in patients with chronic obstructive pulmonary disease

et al. 2021

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) today remains one of the most important problems of modern medicine. The social significance of this disease is determined by the annual health care costs for treating patients with exacerbated COPD, as well as the still high mortality and disability rates worldwide. The main goals of COPD treatment are to slow the rate of disease progression, control the symptoms, reduce the frequency of exacerbations and hospitalizations, and reduce the risk of future exacerbations. Currently, the main groups of drugs for basic therapy of COPD are inhaled prolonged bronchodilators from the groups of β2-adrenergic agonists and M-anticholinergics, as well as their combinations. Patients with COPD and bronchial asthma, as well as patients with COPD with elevated levels of eosinophils and frequent exacerbations, inhaled glucocorticosteroids (ICS) are used. It has been proven that the addition of corticosteroids to LABA in patients with moderate to severe COPD and frequent exacerbations has a more effective influence on pulmonary function and the number of exacerbations. Clinical studies have shown the relationship between the level of blood eosinophilia and the clinical effects of preventing future exacerbations when using iCS in combination with LABA. In our clinical observation, in patient with moderate COPD and blood eosinophilia > 300 cells/μL, when prescribing monotherapy with long-acting agonists, frequent exacerbations of the disease were noted. The addition of corticosteroids to monotherapy with a long-acting agonist made it possible to influence the frequency of exacerbations and reduce the level of eosinophils in the blood.

show abstract

A role of budesonide/formoterol fixed combination in the treatment of stable chronic obstructive pulmonary disease. A conclusion of the Expert Council of the Volga Federal district of Russia

Cited by 3 publications

References 40 publications

Outpatient pulmonology in contemporary national recommendations and research

Outpatient pulmonology in contemporary national recommendations and research

Peripheral blood eosinophil count in COPD: literature data and new findings

Clinical experience of using formoterol/budesonide in patients with chronic obstructive pulmonary disease

Contact Info

Product

Resources

About